Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month …

G Tepe, J Laird, P Schneider, M Brodmann… - Circulation, 2015 - Am Heart Assoc
Background—Drug-coated balloons (DCBs) have shown promise in improving the
outcomes for patients with peripheral artery disease. We compared a paclitaxel-coated …

Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month …

G Tepe, J Laird, P Schneider, M Brodmann, P Krishnan… - Circulation, 2014 - europepmc.org
Background Drug-coated balloons (DCBs) have shown promise in improving the outcomes
for patients with peripheral artery disease. We compared a paclitaxel-coated balloon with …

[PDF][PDF] Drug-Coated Balloon Versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease

G Tepe, J Laird, P Schneider, M Brodmann, P Krishnan… - Circulation, 2015 - Citeseer
Background—Drug-coated balloons (DCBs) have shown promise in improving the
outcomes for patients with peripheral artery disease. We compared a paclitaxel-coated …

[PDF][PDF] Drug-Coated Balloon Versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease

G Tepe, J Laird, P Schneider, M Brodmann, P Krishnan… - Circulation, 2015 - academia.edu
Background—Drug-coated balloons (DCBs) have shown promise in improving the
outcomes for patients with peripheral artery disease. We compared a paclitaxel-coated …

Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month …

G Tepe, J Laird, P Schneider, M Brodmann, P Krishnan… - 2015 - pubmed.ncbi.nlm.nih.gov
Background Drug-coated balloons (DCBs) have shown promise in improving the outcomes
for patients with peripheral artery disease. We compared a paclitaxel-coated balloon with …

Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease 12-month …

G Tepe, J Laird, P Schneider, M Brodmann… - CIRCULATION, 2015 - iris.unime.it
Background: Drug-coated balloons (DCBs) have shown promise in improving the outcomes
for patients with peripheral artery disease. We compared a paclitaxel-coated balloon with …

Drug-Coated Balloon Versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease

G Tepe, J Laird, P Schneider, M Brodmann… - Circulation, 2015 - Am Heart Assoc
Background—Drug-coated balloons (DCBs) have shown promise in improving the
outcomes for patients with peripheral artery disease. We compared a paclitaxel-coated …

Drug-Coated Balloon Versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease

G Tepe, J Laird, P Schneider, M Brodmann, P Krishnan… - Circulation, 2015 - cir.nii.ac.jp
< jats: sec>< jats: title> Background—</jats: title>< jats: p> Drug-coated balloons (DCBs)
have shown promise in improving the outcomes for patients with peripheral artery disease …

[HTML][HTML] Drug-Coated Balloon Versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and Popliteal Peripheral Artery …

G Tepe, J Laird, P Schneider, M Brodmann… - Circulation, 2015 - ncbi.nlm.nih.gov
Background—Drug-coated balloons (DCBs) have shown promise in improving the
outcomes for patients with peripheral artery disease. We compared a paclitaxel-coated …

Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month …

G Tepe, J Laird, P Schneider, M Brodmann, P Krishnan… - Circulation, 2014 - europepmc.org
Background Drug-coated balloons (DCBs) have shown promise in improving the outcomes
for patients with peripheral artery disease. We compared a paclitaxel-coated balloon with …